Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR) announced its earnings results on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04, Briefing.com reports. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 37.83%. The company had revenue of $10.30 million during the quarter, compared to analyst estimates of $14.24 million. During the same period in the previous year, the business earned ($0.70) earnings per share. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $37.40 on Friday. The firm’s 50-day simple moving average is $38.52 and its two-hundred day simple moving average is $29.33. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $45.31.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on KYMR shares. Stifel Nicolaus upped their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Piper Sandler boosted their price target on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Truist Financial boosted their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.10.

Insider Activity

In other news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the sale, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the sale, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Bruce Booth sold 71,764 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the transaction, the director now owns 806,697 shares in the company, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. Insiders have sold a total of 474,051 shares of company stock worth $19,624,211 over the last 90 days. 16.67% of the stock is currently owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.